suma/seizures

TECHNICAL FIELD The disclosure relates to patient monitoring, and, more particularly, to collecting information to evaluate a patient condition. BACKGROUND Some neurological disorders, such as epilepsy, are characterized by the occurrence of seizures. Seizures may be attributable to abnormal

FIELD OF THE INVENTION The present invention is directed to a dietary supplement for treatment of behavioral problems in canines and seizures in canines and felines and, more particularly, to a dietary supplement which includes taurine in a liquid lecithin base. BACKGROUND OF THE INVENTION Taurine

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to certain N-alkyl imidazoles substituted on the alkyl chain by a cyclic ketal moiety and an optionally substituted biphenyl substituent which are useful as anticonvulsant agents in mammals. The invention also

FIELD OF THE INVENTION The present invention relates, by way of novel industrial products, to nicotinoylpiperazine derivatives, i.e., more precisely, to the 4-aryl-1-nicotinoylpiperazine compounds of formula I below and to addition salts thereof. It further relates to the method for the preparation

BACKGROUND OF THE INVENTION Morphological changes occur in the adult vertebrate brain both during normal learning and in various neuropathologies such as epilepsy and Alzheimer's disease (Refs. 1-3). These changes include neurodegeneration and more subtle remodeling of the cellular architecture, and

BACKGROUND OF THE INVENTION 1. Field of Invention This invention relates to a system and method for temporal and spatial detection of seizure onset. Particularly, it relates to a system and method for temporal and spatial detection of seizure onset that utilizes a unique scientific approach to

BACKGROUND OF THE INVENTION This invention relates to seizure monitors, and more particularly relates to means for monitoring movements attributable to seizures and convulsions of patients having epilepsy or other seizure disorders. As is well known by those skilled in the art, it is common practice

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a brain dysfunction and seizure detector monitor and system, and a method of detecting brain dysfunction and/or seizure of a subject. The present invention preferably is a system capable of detecting in real time

FIELD OF THE INVENTION The present invention is directed to predicting the onset of epileptic seizures, and more specifically to a method and apparatus for automatically interpreting information representing the activity of the brain so as to predict the onset of a seizure in order to alert a

RELATED APPLICATIONS Related hereto are U.S. patent application Ser. No. (380,973) and U.S. patent application Ser. No. (380,972), both filed on the same date as this application. BACKGROUND OF THE INVENTION This invention relates to novel 2H-benzothieno[3,2-c]pyrazol-3-amine derivatives, to

FIELD OF THE INVENTION This invention relates to a method for modulating .alpha..sub.2 subtype GABA.sub.A receptors and method for treating a subject afflicted with a disease alleviated by modulating GABA.sub.A receptors with heterocyclic compounds, more particularly, to substituted 7-arylindazole,

FIELD OF THE INVENTION This invention relates to a method for modulating .alpha..sub.2 subtype GABA.sub.A receptors and method for treating a subject afflicted with a disease alleviated by modulating GABA.sub.A receptors with heterocyclic compounds, more particularly, to substituted

FIELD OF THE DISCLOSURE The present disclosure is related to new medical uses of the synthetic neurosteroid analogue ganaxolone. BACKGROUND Ganaxolone (3.alpha.-hydroxy-3.beta.-methyl-5.alpha.-pregnan-20-one, (3.alpha., 5.alpha.)-3-hydroxy-3-methylpregnan-20-one, or CCD 1042) is a synthetic

FIELD OF THE DISCLOSURE The present disclosure is related to new medical uses of the synthetic neurosteroid analogue ganaxolone. BACKGROUND Ganaxolone (3.alpha.-hydroxy-3.beta.-methyl-5.alpha.-pregnan-20-one, (3.alpha.,5.alpha.)-3-hydroxy-3-methylpregnan-20-one, or CCD 1042) is a synthetic

FIELD OF THE INVENTION The present invention is directed towards specific knockout animals and their use as animal models. More specifically, the knockout animals contain a disruption in the genes encoding p19.sup.INK4d and p27.sup.KIP1. Corresponding cells which are amenable to tissue culture are